2010
THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME.
ŘIHÁČEK, Ivan; Petr FRÁŇA; Daniel SCHWARZ; Martin PLACHÝ; Miroslav SOUČEK et. al.Základní údaje
Originální název
THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME.
Název česky
Normalizovaný smoothness index a populační RDH index losartanu a telmisartanu u pacientů s čerstvě zjištěnou hypertenzí a metabolickým syndromem
Název anglicky
THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME.
Autoři
ŘIHÁČEK, Ivan; Petr FRÁŇA; Daniel SCHWARZ; Martin PLACHÝ a Miroslav SOUČEK
Vydání
20th European meeting on Hypertension, Oslo, 18-21.6.2010. 2010
Další údaje
Jazyk
čeština
Typ výsledku
Konferenční abstrakt
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Organizační jednotka
Lékařská fakulta
ISSN
UT WoS
000283023404270
Klíčová slova česky
smoothness index; RDH index; telmisartan; losartan
Klíčová slova anglicky
smoothness index; RDH index; telmisartane; losartane
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 17. 1. 2011 13:02, MUDr. Ivan Řiháček, Ph.D.
V originále
Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Results: systolic blood pressure(SBP)normalized smoothness index of losartane was 1,10, telmisartane 0,96, diastolic blood pressure (DBP) normalized smoothness index of losartane was 0,81, telmisartane 0,80. RHP index for SBP for losartane was 24,24,0, for telmisartane 24,24,0, for DBP for losartane 24,24,0, for telmisartane 21,15,2. Cnclusions: losartane have reasonably better homogenous effect on blood pressure than telmisartane.
Anglicky
Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Results: systolic blood pressure(SBP)normalized smoothness index of losartane was 1,10, telmisartane 0,96, diastolic blood pressure (DBP) normalized smoothness index of losartane was 0,81, telmisartane 0,80. RHP index for SBP for losartane was 24,24,0, for telmisartane 24,24,0, for DBP for losartane 24,24,0, for telmisartane 21,15,2. Cnclusions: losartane have reasonably better homogenous effect on blood pressure than telmisartane.
Návaznosti
| MSM0021622402, záměr |
|